TCBPW Gross Profit from 2010 to 2024

TCBPW Stock

USD 0.02 0 24.67%

TC BioPharm Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit will likely drop to about 3.1 M in 2024. Gross Profit is the profit TC BioPharm plc makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

4.4 M

Current Value

3.1 M

Quarterly Volatility

612.4 K

Credit Downgrade

Yuan Drop

Covid

Check TC BioPharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among TC BioPharm's main balance sheet or income statement drivers, such as Interest Income of 1.9 K, Depreciation And Amortization of 638 K or Interest Expense of 78.9 K, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.3. TCBPW financial statements analysis is a perfect complement when working with TC BioPharm Valuation or Volatility modules.

Check out the analysis of TC BioPharm Correlation against competitors.

Latest TC BioPharm's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of TC BioPharm plc over the last few years. Gross profit is a required income statement account that reflects total revenue of TC BioPharm plc minus its cost of goods sold. It is profit before TC BioPharm operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. TC BioPharm's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in TC BioPharm's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 0

10 Years Trend

Pretty Stable

Compare to Others All Fundamentals

Gross Profit

Timeline

TCBPW Gross Profit Regression Statistics

	Arithmetic Mean	3,305,294
	Geometric Mean	3,241,771
	Coefficient Of Variation	18.53
	Mean Deviation	382,756
	Median	3,426,846
	Standard Deviation	612,430
	Sample Variance	375.1B
	Range	2.4M
	R-Value	(0.12)
	Mean Square Error	398.5B
	R-Squared	0.01
	Significance	0.68
	Slope	(15,912)
	Total Sum of Squares	5.3T

TCBPW Gross Profit History

	2024	3.1 M
	2023	4.4 M
	2022	3.8 M
	2020	2 M

Other Fundumenentals of TC BioPharm plc

Gross Profit Margin

TC BioPharm Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Net Invested Capital	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Intangible Assets	Common Stock	Short Long Term Debt
Total Assets		0.47	0.05	-0.49	0.23	-0.38	0.6	-0.26	0.41	0.62	0.18	0.53	-0.46	-0.3	0.53	-0.15
Total Stockholder Equity	0.47		-0.54	-0.97	-0.1	-0.03	0.02	-0.96	0.96	0.44	-0.03	0.9	-0.89	0.15	0.0	-0.55
Current Deferred Revenue	0.05	-0.54		0.43	0.85	-0.78	0.68	0.49	-0.74	-0.53	0.81	-0.15	0.12	-0.81	0.71	0.91
Net Debt	-0.49	-0.97	0.43		0.06	0.13	-0.01	0.94	-0.91	-0.47	-0.02	-0.87	0.88	-0.15	0.0	0.53
Retained Earnings	0.23	-0.1	0.85	0.06		-0.88	0.87	0.06	-0.37	-0.54	0.99	0.34	-0.35	-0.96	0.91	0.87
Accounts Payable	-0.38	-0.03	-0.78	0.13	-0.88		-0.76	0.0	0.22	0.39	-0.9	-0.39	0.43	0.86	-0.78	-0.68
Net Receivables	0.6	0.02	0.68	-0.01	0.87	-0.76		0.06	-0.2	-0.18	0.81	0.41	-0.36	-0.92	0.99	0.67
Total Liab	-0.26	-0.96	0.49	0.94	0.06	0.0	0.06		-0.9	-0.3	-0.03	-0.87	0.88	-0.17	0.05	0.48
Net Invested Capital	0.41	0.96	-0.74	-0.91	-0.37	0.22	-0.2	-0.9		0.58	-0.31	0.74	-0.72	0.4	-0.23	-0.75
Total Current Assets	0.62	0.44	-0.53	-0.47	-0.54	0.39	-0.18	-0.3	0.58		-0.58	0.15	-0.1	0.54	-0.26	-0.78
Capital Stock	0.18	-0.03	0.81	-0.02	0.99	-0.9	0.81	-0.03	-0.31	-0.58		0.4	-0.43	-0.94	0.86	0.83
Net Working Capital	0.53	0.9	-0.15	-0.87	0.34	-0.39	0.41	-0.87	0.74	0.15	0.4		-0.99	-0.3	0.41	-0.13
Short Term Debt	-0.46	-0.89	0.12	0.88	-0.35	0.43	-0.36	0.88	-0.72	-0.1	-0.43	-0.99		0.28	-0.37	0.11
Intangible Assets	-0.3	0.15	-0.81	-0.15	-0.96	0.86	-0.92	-0.17	0.4	0.54	-0.94	-0.3	0.28		-0.94	-0.87
Common Stock	0.53	0.0	0.71	0.0	0.91	-0.78	0.99	0.05	-0.23	-0.26	0.86	0.41	-0.37	-0.94		0.72
Short Long Term Debt	-0.15	-0.55	0.91	0.53	0.87	-0.68	0.67	0.48	-0.75	-0.78	0.83	-0.13	0.11	-0.87	0.72

Click cells to compare fundamentals

About TC BioPharm Financial Statements

TC BioPharm investors use historical fundamental indicators, such as TC BioPharm's Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in TC BioPharm. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Gross Profit	4.4 M	3.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for TCBPW Stock Analysis

When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC